Safety of a Second Dose of Biken's Varicella Vaccine
Primary Purpose
Varicella
Status
Completed
Phase
Phase 4
Locations
Argentina
Study Type
Interventional
Intervention
Live Attenuated Varicella Virus Vaccine
Sponsored by
About this trial
This is an interventional prevention trial for Varicella focused on measuring varicella-zoster virus, varicella
Eligibility Criteria
Inclusion Criteria :
- Aged 4 to 6 years on the day of inclusion.
- Informed consent form signed by the parent(s) or legal guardian and by an independent witness.
- Subject and parent/guardian able to attend all scheduled visits and comply with all trial procedures.
- Written documentation of receipt of a first dose of Varicella Biken vaccine more than 3 months before inclusion.
Exclusion Criteria:
- Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the trial vaccination.
- Planned participation in another clinical trial during the present trial period.
- Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy.
- Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or to a vaccine containing any of the same substances.
- Chronic illness, at a stage that could interfere with trial conduct or completion, in the opinion of the investigator.
- Receipt of any vaccine in the 4 weeks preceding the trial vaccination;
- Planned receipt of any vaccine in the 4 weeks following the trial vaccination.
- Known Human Immunodeficiency Virus (HIV), Hepatitis B surface antigen, or Hepatitis C seropositivity.
- History of varicella infection (confirmed either clinically, serologically or microbiologically).
- Previous vaccination against varicella disease with a vaccine different from Varicella Biken vaccine.
- Febrile illness (temperature ≥ 37.5°C) or moderate or severe acute illness/infection on the day of vaccination, according to investigator judgment.
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
1
Arm Description
Outcomes
Primary Outcome Measures
To provide information concerning the safety after administration of Varicella vaccine
Secondary Outcome Measures
Full Information
NCT ID
NCT00830648
First Posted
January 27, 2009
Last Updated
June 6, 2013
Sponsor
Sanofi Pasteur, a Sanofi Company
1. Study Identification
Unique Protocol Identification Number
NCT00830648
Brief Title
Safety of a Second Dose of Biken's Varicella Vaccine
Official Title
Safety of a Second Dose of Biken's Varicella Vaccine Administered at 4 to 6 Years of Age in Healthy Children in Argentina
Study Type
Interventional
2. Study Status
Record Verification Date
June 2013
Overall Recruitment Status
Completed
Study Start Date
January 2009 (undefined)
Primary Completion Date
October 2009 (Actual)
Study Completion Date
December 2009 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sanofi Pasteur, a Sanofi Company
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The objective of the present study is to assess and document the safety of a second dose of Varicella Biken vaccine administered at 4 to 6 years of age in healthy children having previously received a first dose of Varicella Biken vaccine.
All subjects will receive a second dose of Varicella vaccine (Varicella Biken) at 4 to 6 years of age.
The expected total duration of follow-up (first visit to last visit) for each subject will be one month.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Varicella
Keywords
varicella-zoster virus, varicella
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
122 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Intervention Type
Biological
Intervention Name(s)
Live Attenuated Varicella Virus Vaccine
Other Intervention Name(s)
Varicela Biken
Intervention Description
0.5 mL, Subcutaneous
Primary Outcome Measure Information:
Title
To provide information concerning the safety after administration of Varicella vaccine
Time Frame
one month after vaccination
10. Eligibility
Sex
All
Minimum Age & Unit of Time
4 Years
Maximum Age & Unit of Time
6 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria :
Aged 4 to 6 years on the day of inclusion.
Informed consent form signed by the parent(s) or legal guardian and by an independent witness.
Subject and parent/guardian able to attend all scheduled visits and comply with all trial procedures.
Written documentation of receipt of a first dose of Varicella Biken vaccine more than 3 months before inclusion.
Exclusion Criteria:
Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the trial vaccination.
Planned participation in another clinical trial during the present trial period.
Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy.
Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or to a vaccine containing any of the same substances.
Chronic illness, at a stage that could interfere with trial conduct or completion, in the opinion of the investigator.
Receipt of any vaccine in the 4 weeks preceding the trial vaccination;
Planned receipt of any vaccine in the 4 weeks following the trial vaccination.
Known Human Immunodeficiency Virus (HIV), Hepatitis B surface antigen, or Hepatitis C seropositivity.
History of varicella infection (confirmed either clinically, serologically or microbiologically).
Previous vaccination against varicella disease with a vaccine different from Varicella Biken vaccine.
Febrile illness (temperature ≥ 37.5°C) or moderate or severe acute illness/infection on the day of vaccination, according to investigator judgment.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Director
Organizational Affiliation
Sanofi Pasteur Inc.
Official's Role
Study Director
Facility Information:
City
Buenos Aires
ZIP/Postal Code
C1406DGI
Country
Argentina
12. IPD Sharing Statement
Links:
URL
http://www.sanofipasteur.com
Description
Related Info
Learn more about this trial
Safety of a Second Dose of Biken's Varicella Vaccine
We'll reach out to this number within 24 hrs